sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022

Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate...

Home / Categories / Healthcare
Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022
Hemophilia A Treatment Market [By...
Report Code
RO1/107/1019

Publish Date
01/Feb/2018

Pages
100
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics. The increasing prevalent population of Hemophilia A and the rise in demand of the prophylactics treatments in developed markets will have a great impact on this market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com